186 related articles for article (PubMed ID: 37399858)
21. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
22. The Bidirectional Link Between Diabetes and Kidney Disease: Mechanisms and Management.
Kumar M; Dev S; Khalid MU; Siddenthi SM; Noman M; John C; Akubuiro C; Haider A; Rani R; Kashif M; Varrassi G; Khatri M; Kumar S; Mohamad T
Cureus; 2023 Sep; 15(9):e45615. PubMed ID: 37868469
[TBL] [Abstract][Full Text] [Related]
23. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
Coccheri S
Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
[TBL] [Abstract][Full Text] [Related]
24. [Should the occurrence of a first coronary event change the management of diabetes?].
Timsit J; Dubois-Laforgue D
Arch Mal Coeur Vaiss; 2000 Dec; 93 Spec No 4():39-44. PubMed ID: 11296461
[TBL] [Abstract][Full Text] [Related]
25. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
[TBL] [Abstract][Full Text] [Related]
26. Medical management of the diabetic patient with coronary artery disease.
Karastergiou K; Kaski JC
Curr Pharm Des; 2008; 14(25):2527-36. PubMed ID: 18991670
[TBL] [Abstract][Full Text] [Related]
27. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.
Hoerger TJ; Ahmann AJ
J Manag Care Pharm; 2008 Feb; 14(1 Suppl C):S2-14; quiz 15-6. PubMed ID: 18240890
[TBL] [Abstract][Full Text] [Related]
28. Modern approach to the clinical management of non-alcoholic fatty liver disease.
Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
[TBL] [Abstract][Full Text] [Related]
29. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
30. [Is type-2 diabetes mellitus preventable?].
Jermendy G
Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
[TBL] [Abstract][Full Text] [Related]
31. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.
Sharma N; Chakole S; Wandile B
Cureus; 2023 Oct; 15(10):e46946. PubMed ID: 38021670
[TBL] [Abstract][Full Text] [Related]
32. The connection between hypertension and diabetes and their role in heart and kidney disease development.
Hezam AAM; Shaghdar HBM; Chen L
J Res Med Sci; 2024; 29():22. PubMed ID: 38855561
[TBL] [Abstract][Full Text] [Related]
33. Exploring the Complex Connection Between Diabetes and Cardiovascular Disease: Analyzing Approaches to Mitigate Cardiovascular Risk in Patients With Diabetes.
Jyotsna F; Ahmed A; Kumar K; Kaur P; Chaudhary MH; Kumar S; Khan E; Khanam B; Shah SU; Varrassi G; Khatri M; Kumar S; Kakadiya KA
Cureus; 2023 Aug; 15(8):e43882. PubMed ID: 37746454
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.
Naci H; Ioannidis JP
BMJ; 2013 Oct; 347():f5577. PubMed ID: 24473061
[TBL] [Abstract][Full Text] [Related]
35. Heart failure and diabetes mellitus: epidemiology and management of an alarming association.
Cohen-Solal A; Beauvais F; Logeart D
J Card Fail; 2008 Sep; 14(7):615-25. PubMed ID: 18722328
[TBL] [Abstract][Full Text] [Related]
36. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.
Zhang F; Ji L; Hong T; Guo L; Li Y; Zhu Z; Liu X; Liu F; Tang L; Zhang Y; Li J; Lü Q; Tong N
J Evid Based Med; 2022 Jun; 15(2):168-179. PubMed ID: 35715995
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.
Joseph JJ; Deedwania P; Acharya T; Aguilar D; Bhatt DL; Chyun DA; Di Palo KE; Golden SH; Sperling LS;
Circulation; 2022 Mar; 145(9):e722-e759. PubMed ID: 35000404
[TBL] [Abstract][Full Text] [Related]
38. Use of drugs related to the treatment of diabetes mellitus and other cardiovascular risk factors in the Spanish population. The Di@bet.es study.
Rojo-Martínez G; Valdés S; Colomo N; Lucena MI; Gaztambide S; Gomis R; Casamitjana R; Carmena R; Catalá M; Martínez-Larrad MT; Serrano-Ríos M; Castaño L; Vendrell J; Girbés J; Franch J; Vázquez JA; Mora-Peces I; Urrutia I; Pascual-Manich G; Ortega E; Menéndez E; Delgado E; Bordiú E; Castell C; López-Alba A; Goday A; Calle A; Bosch-Comas A; Soriguer F
Rev Esp Cardiol (Engl Ed); 2013 Nov; 66(11):854-63. PubMed ID: 24773992
[TBL] [Abstract][Full Text] [Related]
39. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.
Gyberg V; Kotseva K; Dallongeville J; Backer GD; Mellbin L; Rydén L; Wood D; Bacquer DD;
Eur J Prev Cardiol; 2015 Jun; 22(6):753-61. PubMed ID: 24691153
[TBL] [Abstract][Full Text] [Related]
40. Effects of Mobile Text Messaging on Glycemic Control in Patients With Coronary Heart Disease and Diabetes Mellitus: A Randomized Clinical Trial.
Huo X; Krumholz HM; Bai X; Spatz ES; Ding Q; Horak P; Zhao W; Gong Q; Zhang H; Yan X; Sun Y; Liu J; Wu X; Guan W; Wang X; Li J; Li X; Spertus JA; Masoudi FA; Zheng X
Circ Cardiovasc Qual Outcomes; 2019 Sep; 12(9):e005805. PubMed ID: 31474119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
